Candid Therapeutics Partners with EpimAb Biotherapeutics to Develop T-Cell Engagers for Autoimmune Indications
Shots:
- Candid Therapeutics has signed a strategic research collaboration agreement with EpimAb Biotherapeutics for the discovery & development of novel T-cell Engager candidates targeting autoimmune disorders
- As per the agreement, EpimAb will receive an aggregate of up to $1B in upfront as well as development & sales milestones plus additional net-sales based royalties
- Furthermore, Candid secures exclusive global development & commercialization rights of these candidates
Ref: EpimAb Biotherapeutics | Image: Candid Therapeutics & EpimAb Biotherapeutics
Related News:- HUTCHMED Secures $10M Milestone Payment from Takeda Following the First Reimbursement of Fruzaqla in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
